NASDAQ:PMCB
PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc.'s revenue was $0 in fiscal 2026. The diluted share count rose 14.3%.Summary generated from PharmaCyte Biotech, Inc.'s SEC filings. Latest annual report filed Jul 29, 2026.
Key statistics
Fiscal 2026 from SEC filings. MethodologyRevenue (FY26)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−45.6%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+14.3%
Financials
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating income | −4 | −6 | −9 | −4 | −7 |
| Net income | −4 | −4 | 0 | 31 | −19 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jul 31, 2026
Sep 14, 2026 - 10-KAnnual report for the fiscal year ended Apr 30, 2026
Jul 29, 2026 - 4Insider transaction report
Apr 2, 2026 - 4Insider transaction report
Apr 2, 2026 - 8-KDirector or officer change
Apr 2, 2026 - 10-QQuarterly report for the period ended Jan 31, 2026
Mar 17, 2026 - DEF 14AProxy statement
Mar 9, 2026 - 10-QQuarterly report for the period ended Oct 31, 2025
Dec 18, 2025